ALLMedicine™ Parathyroid Hormone-related Peptide Center
Research & Reviews 171 results
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.
Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792014
BMC Endocrine Disorders; Brun VH, Knutsen E et. al.
Jan 8th, 2021 - Hypercalcemia of malignancy is relatively common in several cancers. However, in colorectal cancer, paraneoplastic phenomena that cause hypercalcemia is uncommon. In the few cases that are reported, secretion of parathyroid hormone-related peptide...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469
The Journal of Clinical Endocrinology and Metabolism; Cosman F, Peterson LR et. al.
Jul 13th, 2020 - Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. We assessed the cardiovascular safety profile of abaloparatide. ...
https://doi.org/10.1177/1947603519894727
Cartilage Rajagopal K, Ramesh S et. al.
Jan 1st, 2020 - Chondrogenic differentiation of mesenchymal stem cells (MSCs) into hyaline cartilage is complicated by terminal hypertrophic differentiation. In growth plate, parathyroid hormone-related peptide (1-34) (PTHrP) plays a crucial role in maintaining c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608053
Oral Diseases; Tokavanich N, Gupta A et. al.
Dec 5th, 2019 - Primary failure of eruption (PFE) is a genetic disorder exhibiting the cessation of tooth eruption. Loss-of-function mutations in parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH/PTHrP receptor, PPR) were reporte...
Clinicaltrials.gov 173 results
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.
Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792014
BMC Endocrine Disorders; Brun VH, Knutsen E et. al.
Jan 8th, 2021 - Hypercalcemia of malignancy is relatively common in several cancers. However, in colorectal cancer, paraneoplastic phenomena that cause hypercalcemia is uncommon. In the few cases that are reported, secretion of parathyroid hormone-related peptide...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469
The Journal of Clinical Endocrinology and Metabolism; Cosman F, Peterson LR et. al.
Jul 13th, 2020 - Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. We assessed the cardiovascular safety profile of abaloparatide. ...
https://doi.org/10.1177/1947603519894727
Cartilage Rajagopal K, Ramesh S et. al.
Jan 1st, 2020 - Chondrogenic differentiation of mesenchymal stem cells (MSCs) into hyaline cartilage is complicated by terminal hypertrophic differentiation. In growth plate, parathyroid hormone-related peptide (1-34) (PTHrP) plays a crucial role in maintaining c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608053
Oral Diseases; Tokavanich N, Gupta A et. al.
Dec 5th, 2019 - Primary failure of eruption (PFE) is a genetic disorder exhibiting the cessation of tooth eruption. Loss-of-function mutations in parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH/PTHrP receptor, PPR) were reporte...
News 1 results
https://www.medscape.com/viewarticle/938943
Abstract and Introduction Abstract Context: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. Objectives: We asses...
